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Structural basis of checkpoint blockade by
monoclonal antibodies in cancer immunotherapy
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Cancer cells express tumour-speciﬁc antigens derived via genetic and epigenetic alterations,
which may be targeted by T-cell-mediated immune responses. However, cancer cells can
avoid immune surveillance by suppressing immunity through activation of speciﬁc inhibitory
signalling pathways, referred to as immune checkpoints. In recent years, the blockade of
checkpoint molecules such as PD-1, PD-L1 and CTLA-4, with monoclonal antibodies has
enabled the development of breakthrough therapies in oncology, and four therapeutic
antibodies targeting these checkpoint molecules have been approved by the FDA for the
treatment of several types of cancer. Here, we report the crystal structures of checkpoint
molecules in complex with the Fab fragments of therapeutic antibodies, including
PD-1/pembrolizumab, PD-1/nivolumab, PD-L1/BMS-936559 and CTLA-4/tremelimumab.
These complex structures elucidate the precise epitopes of the antibodies and the molecular
mechanisms underlying checkpoint blockade, providing useful information for the improve-
ment of monoclonal antibodies capable of attenuating checkpoint signalling for the treatment
of cancer.
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A
s the immune system plays an important role in
controlling cancer, utilizing the immune system to
eliminate cancer holds great potential. Although various
immunotherapeutic approaches have been shown to enhance the
immune system’s ability to modulate cancer, therapeutic
antibodies that target regulatory pathways in T-cells to enhance
antitumor immune responses, have attracted signiﬁcant recent
attention.
T-cell-mediated immune responses are triggered through the
recognition of antigenic peptide/HLA complexes on the surface of
antigen presenting cells (APCs) by T-cell receptors and are tightly
regulated by antigen-independent co-receptor signals, either
costimulatory or coinhibitory, providing the optimal balance
between immune responses to antigens and maintenance of self-
tolerance under normal physiological conditions1–3. Costimu-
latory signals are required to enhance and sustain the function of
T-cells, the most important of which is provided by the
interaction of CD28, a co-receptor on T-cells, with its ligands
B7-1 and B7-2 on APCs (refs 4,5). In contrast, the binding of the
same B7 ligands to cytotoxic T lymphocyte-associated antigen
4 (CTLA-4), a CD28 homologue with 31% sequence identity,
delivers coinhibitory signals for down-regulation of immune
responses6. Programmed death-1 (PD-1) is also an antigen-
independent co-receptor and plays a pivotal role in modulating
immune responses7. The interaction of PD-1 with its ligands PD-
L1 and PD-L2 on APCs induces inhibitory signals reducing T-cell
activity8,9. Although both CTLA-4 and PD-1 are coinhibitory
receptors, each plays a non-redundant role in the negative
regulation of immune responses. While engagement of CTLA-4
by B7 ligands attenuates the early activation of naı¨ve and memory
T-cells, PD-1 modulates the function of T-cells later in peripheral
tissues via interaction with PD-L1 and PD-L2 (ref. 10).
As cancer cells harbour genetic and epigenetic modiﬁcations,
tumour-speciﬁc antigens are presented on the cancer cell surface
and can be recognized by T-cells, therefore causing immune
responses11–14. However, cancer cells can also evade immuno-
logical recognition and destruction through the activation of
coinhibitory signalling by overproduction of immune checkpoint
proteins such as PD-1 and CTLA-4 on immune effector cells and
PD-L1 on cancer cells15–17. Furthermore, expression of PD-L1 on
cancer cells can directly lead to the death of antigen-speciﬁc
effector T-cells expressing PD-1 (ref. 18). In an inﬂamed tumour
microenvironment, engagement of PD-1 or CTLA-4 can self-
limit the antitumor immune responses and permit cancer cells to
proliferate unrestrained. Advances in the understanding of the
molecular mechanisms underlying the ability of cancer cells to
suppress immune surveillance have devised strategies to
overcome cancer-induced immune tolerance, thereby protecting
the host from tumour progression. Blockade of the ligand-
receptor interaction of these immune checkpoint molecules can
directly enhance the function of T-cells, which represents a
critical paradigm shift whereby checkpoint blockade aims at
disinhibition of the activity of T-cells compared with the
previous immuno-oncology concept, whereby cancer vaccines
and cytokine therapies aimed at de novo activation of immune
responses.
Monoclonal antibodies blocking immune checkpoints have
demonstrated unprecedented therapeutic beneﬁts in clinical trials
and provided a major breakthrough in oncology19–23. While
targeted therapies elicit transient clinical responses because of
acquisition of cancer drug resistance usually occurring within
months after an initial response, the clinical responses of
checkpoint blockade therapies are often durable, with some
patients free from cancer progression for many years19,24,25. The
US Food and Drug Administration (FDA) has approved
monoclonal antibodies that block CTLA-4 (ipilimumab), PD-1
(pembrolizumab and nivolumab), and PD-L1 (atezolizumab) for
the treatment of melanoma, non-small-cell lung cancer, renal cell
carcinoma, Hodgkin lymphoma and bladder cancer. As a number
of clinical trials for antibodies targeting immune checkpoints are
ongoing, additional approvals are expected for other antibodies
and expanded indications in the near future26.
There have been a number of structural studies for immune
checkpoint molecules. The structures of the extracellular portion
of CTLA-4 revealed an unusual mode of CTLA-4 dimerization
that places the B7 binding sites distal to the dimerization
interface27. The crystal structures of CTLA-4 in complex with its
B7 ligands showed the formation of a unique alternating network
of bivalent CTLA-4 and B7-1/2 dimers, providing a structural
basis for formation of unusually stable signalling complexes to
regulate T-cell responsiveness within the immunological
synapse28,29. The structures of murine PD-1 in complex with
human PD-L1, murine PD-1 in complex with murine PD-L2, and
human PD-1 in complex with human PD-L1 have established
the structural foundations of the interaction of PD-1 with
its ligands30–33. These structural studies for checkpoint molecules
and their binding complexes have provided invaluable
information for understanding the molecular mechanism of
coinhibitory signals of T-cells through the communication of
checkpoint molecules.
As the exact epitope and mechanism are crucial elements for
antibody drugs, we report the crystal structures of checkpoint
molecules in complex with the Fab fragments of therapeutic
antibodies approved by the FDA or currently undergoing clinical
trials, and reveal the binding modes of the complexes and the
conformational changes induced by the antibody binding, thereby
providing a structural basis of checkpoint blockade by mono-
clonal antibodies for the treatment of cancer.
Results
Crystal structures of PD-1 in complex with anti-PD-1 drugs.
Pembrolizumab (trade name KEYTRUDA) is a humanized IgG4
antibody that blocks PD-1 (ref. 26). The FDA approved
pembrolizumab for the treatment of advanced melanoma in
September 2014 and metastatic non-small-cell lung cancer
(NSCLC) in October 2015. The PD-1/pembrolizumab Fab
fragment complex was crystallized and its structure was
determined and reﬁned to a resolution of 2.0 Å (Fig. 1a,b). The
pembrolizumab epitope of PD-1 consists of numerous dis-
continuous segments (Fig. 2a). The formation of hydrogen bonds
between PD-1 and pembrolizumab involves side chain atoms of
PD1N66, PD1T76, PD1K78, PD1S87 and PD1K131 and main chain
atoms of PD1F63, PD1E84, PD1S87, PD1G90 and PD1A132, whereas a
salt bridge is formed between PD1D85 and heavyR99. In addition,
the main chain atom of PD1K78 and the side chain atoms of
PD1S87 and PD1D85 participate in water-mediated interactions
with heavyN52 and heavyR99. The residues of PD-1 involved in van
der Waals contact with pembrolizumab are PD1S62, PD1V64,
PD1Y68, PD1Q75, PD1D77, PD1A81, PD1F82, PD1P83, PD1R86,
PD1Q88, PD1P89, PD1G90, PD1I126, PD1L128, PD1A129, and
PD1I134. The paratope of pembrolizumab consists of heavyT30,
heavyY33, and heavyY35 of HCDR1; heavyN52, heavyS54, heavyN55,
heavyG57, heavyT58, and heavyN59 of HCDR2; heavyR99, heavyY101,
heavyR102, heavyF103, heavyD104, heavyM105, and
heavyD108 of HCDR3; lightT31, lightS32, lightY34, and lightY36 of
LCDR1; lightY53, lightL54, lightY57, and lightE59 of LCDR2; and
lightS95, lightR96, lightD97, lightL98 and lightL100 of LCDR3.
Nivolumab (trade name OPDIVO) is a fully human IgG4 that
blocks PD-1 (ref. 26). The FDA approved nivolumab for the
treatment of melanoma in December 2014, NSCLC in March
2015, renal cell carcinoma in November 2015, and Hodgkin
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lymphoma in May 2016. The PD-1/nivolumab Fab complex and
free nivolumab Fab fragment were crystallized and their
structures were determined and reﬁned to a resolution of
3.3 and 1.9 Å, respectively (Fig. 1c,d). In the complex structure,
the formation of hydrogen bonds between PD-1 and nivolumab
involves side chain atoms of PD1D29, PD1R30, PD1S60 and
PD1K131 and main chain atoms of PD1P28, PD1L128, PD1A129,
PD1P130, and PD1A132. The PD-1 residues involved in van der
Waals contact with nivolumab are PD1S27, PD1P28, PD1P31,
PD1E61, PD1A129, PD1P130, PD1K131, PD1A132 and PD1Q133. The
residues of nivolumab involved in the interaction with PD-1 are
heavyG26, heavyI27, heavyN31 and heavyG33 of HCDR1; heavyV50,
heavyW52 and heavyY53 of HCDR2; heavyN99, heavyD100, heavyD101
and heavyY102 of HCDR3; lightL46, lightA55 and lightT56 of LCDR2;
and lightS91 of LCDR3 (Fig. 2b).
The total buried surface areas of the PD-1/pembrolizumab and
PD-1/nivolumab complexes are 2,126Å2 and 1,487Å2, respec-
tively, compared with 1,970Å2 for PD-1/PD-L1 (ref. 30). The
epitopes of the two antibodies directly occupy part of the PD-L1
binding site (Fig. 2c). In addition, the binding of PD-1 with
pembrolizumab or nivolumab induces optimal conformational
changes in the BC loop (residues 57–63) and the FG loop
(residues 127–134) of PD-1, which are incompatible with PD-L1
binding as they also interact with PD-L1 in distinct conforma-
tions30 (Fig. 3a,b). The C0D loop (residues 81–90) was shown to
be highly ﬂexible in the NMR structure of free PD-1 (ref. 31), and
disordered in the crystal structure of the PD-1/PD-L1 complex as
a result of the lack of interaction30,32,33. However, most of the
residues of the C0D loop in the PD-1/pembrolizumab complex are
involved in the interactions with pemrolizumab with a clear
electron density around them, implying that the C0D loop
contributes to the binding afﬁnity for pembrolizumab. This loop
intrudes into the groove formed by the CDR loops of
pembrolizumab (Fig. 3a,c). The electron density of the C0D
loop in the complex structure of PD-1/nivolumab is also clearly
shown, probably because of the crystal packing interaction despite
the lack of interaction with nivolumab (Fig. 3b). The structural
comparisons of the Fv regions of pembrolizumab and nivolumab
before and after binding to PD-1 show little deviation in the
conformation of the CDRs and minor adjustments in the side
chains involved in the interaction with PD-1, implying that these
antibody drugs maintain the CDR loops in productive binding
conformations prior to interaction with PD-1 (Supplementary
Fig. 1a,b). The high avidity of these two antibodies, which results
from the bivalency of IgG, could also contribute to their tight
binding to PD-1. Taken together, these structural features suggest
that the mechanism by which the anti-PD-1 antibodies block the
PD-1/PD-L1 interaction is through outcompeting PD-L1 for
binding to PD-1.
Crystal structure of PD-L1 in complex with BMS-936559 Fab.
BMS-936559, a fully human IgG4 antibody that blocks PD-L1,
has been shown to induce objective responses in melanoma,
NSCLC, and certain other solid tumours in Phase I clinical
trials34,35. The PD-L1/BMS-936559 Fab fragment complex was
crystallized and its structure was determined and reﬁned to a
resolution of 2.8 Å (Fig. 4). Superposition of the PD-L1 molecules
extracted from PD-1/PD-L1 and PD-L1/BMS-936559 yielded a
root mean s.d. of 0.71Å for all of the Ca atoms, indicating that no
signiﬁcant overall structural difference occurred (Supplementary
Fig. 2). The side-chain atoms of PDL1D49, PDL1Y56 and PDL1H69
and main-chain atom of PDL1A121 participate in the formation of
hydrogen bonds between PD-L1 and BMS-936559, while a
salt bridge is formed by PDL1E58 (Fig. 5a). Numerous residues of
PD-L1, including PDL1A51, PDL1A53, PDL1I54, PDL1Y56, PDL1Q66,
PDL1V68, PDL1H69, PDL1R113, PDL1M115, PDL1S117, PDL1G119,
PDL1G120, PDL1D122 and PDL1Y123, are involved in van der Waals
contact with BMS-936559. The paratope of BMS-936559 consists
of heavyT31 and heavyY32 of HCDR1; heavyI52, heavyI54, heavyF55,
heavyK57, and heavyH59 of HCDR2; heavyK99, heavyS104, heavyG105,
heavyS106, heavyP107 and heavyF108 of HCDR3; lightT32 of LCDR1;
and lightS92, lightN93, and lightW94 of LCDR3. The total buried
surface area of PD-L1/BMS-936559 is 1,349Å2, which is much
smaller than that of PD-1/PD-L1 (1,970Å2) (ref. 30). However,
the epitope of BMS-936559 occupies a large part of the PD-1
binding site (Fig. 5b); in addition, high avidity, resulting from IgG
bivalency, is expected due to the high expression level of PD-L1
in many cancer types36, leading to efﬁcient blockade of the
PD-1/PD-L1 interaction.
Crystal structure of CTLA-4 in complex with tremelimumab Fab.
Tremelimumab is a fully human IgG2 antibody that blocks
CTLA-4. In 2015, tremelimumab was granted Fast Track Desig-
nation and Orphan Drug Designation by the FDA as a potential
treatment for malignant mesothelioma. In addition, tremelimu-
mab is being studied in combination with an anti-PD-L1,
durvalumab, in multiple tumour types37. The CTLA-4/
tremelimumab Fab complex and free tremelimumab Fab were
crystallized and their structures were determined and reﬁned
to a resolution of 2.0 Å and 2.3Å, respectively (Fig. 6). The
a
c d
b
Figure 1 | Crystal structures of PD-1 in complex with anti-PD-1 drugs.
(a) Ribbon representation of the complex structure of PD-1/pembrolizumab
Fab fragment. The heavy and light chains of pembrolizumab are coloured
pink and yellow, respectively. PD-1 in the complex is coloured green.
(b) Stereoview of the 2fo-fc composite omit map (1.2s contour level) at
the interface between PD-1 (green) and pembrolizumab (heavy chain: pink,
light chain: yellow) calculate at 2.0Å resolution. (c) Ribbon representation
of the complex structure of PD-1/nivolumab Fab fragment. The heavy and
light chains of nivolumab are coloured orange and purple, respectively. PD-1
in the complex is coloured green. (d) Stereoview of the 2fo-fc composite
omit map (1.2s contour level) at the interface between PD-1 (green) and
nivolumab (heavy chain: orange, light chain: purple) calculated at 3.3Å
resolution. In a and c, the PD-1/PD-L1 complex (PDB code 4zqk) was
superimposed onto the PD-1 molecule in the PD-1/anti-PD-1 complexes
with mixed ribbon/surface representation. PD-1 and PD-L1 in the PD-1/PD-
L1 complex are coloured pale blue and blue, respectively.
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tremelimumab epitope of CTLA-4 consists of several disconti-
nuous segments (Fig. 7a). The side chain atoms of CTLA4K1
and CTLA4K95 and main chain atoms of CTLA4M3, CTLA4Q41,
CTLA4M99, CTLA4Y104, CTLA4L106, and CTLA4I108 participate in
the formation of hydrogen bonds between CTLA-4 and
tremelimumab, whereas CTLA4E97 participates in salt bridge
formation. A large number of residues, including CTLA4A2,
CTLA4E33, CTLA4R35, CTLA4S44, CTLA4Q45, CTLA4V46, CTLA4E48,
CTLA4L91, CTLA4I93, CTLA4M99, CTLA4P102, CTLA4P103,
CTLA4Y104, CTLA4Y105, CTLA4L106, CTLA4I108, and CTLA4N110,
contribute to van der Waals contact with tremelimumab. The
tremelimumab residues involved in the interaction with CTLA-4
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Figure 2 | Interactions between PD-1 and anti-PD-1 drugs. (a) Stereoview of the detailed PD-1/pembrolizumab interface. (b) Stereoview of the
detailed PD-1/nivolumab interface. In a and b, the carbon atoms of PD-1 and heavy and light chain of anti-PD-1 are coloured grey, green, and purple,
respectively. Hydrogen bonds and a salt bridge are indicated with dashed lines. (c) Surface representations of the PD-1 molecules in the complex structures
of PD-1/PD-L1 (left), PD-1/pembrolizumab (centre) and PD-1/nivolumab (right). The surface of PD-1 in PD-1/PD-L1 is coloured pale blue and the PD-L1
binding site on the surface of PD-1 is coloured blue. The surfaces of PD-1 in PD-1/anti-PD-1 are coloured green. The epitope regions for the heavy and light
chains of pembrolizumab are coloured purple and yellow, respectively. The epitope regions for the heavy and light chains of nivolumab are colored orange
and red, respectively.
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are heavyW52, heavyY53, heavyN57 and heavyY59 of HCDR2;
heavyR101, heavyG102, heavyA103, heavyT104, heavyL105, heavyY106,
heavyY107, heavyY108 and heavyY110 of HCDR3; lightQ27, lightS28,
lightN30 and lightY32 of LCDR1; and lightY91, lightY92, lightS93 and
lightT94 of LCDR3. Superposition of the CTLA-4 molecules
extracted from CTLA-4/tremelimumab and CTLA-4/B7-1 yielded
a root mean square deviation of 1.08Å for all of the Ca atoms,
indicating no signiﬁcant deviation in the two structures except for
several residues at the antibody–antigen interface, which are not
involved in the interaction with B7 ligands (Supplementary
Fig. 3). As observed in the structure of free CTLA-4 and that of
CTLA-4 in complex with B7-1/2, the three consecutive proline
residues of the MYPPPYY (residues 99–105) sequence of the FG
loop of CTLA-4 in complex with tremelimumab adopt an
unusual cis-trans-cis conformation and participate in interactions
with the antibody28,29,38 (Fig. 7a). The tremelimumab epitope
partially occupies the B7-1/2 binding site of CTLA-4, with a
larger interface area between CTLA-4 and tremelimumab (buried
surface area of 1,802Å2) than the receptor–ligand interface
(1,255Å2 for CTLA-4/B7-1 and 1,212Å2 for CTLA-4/B7-2)
(Fig. 7b). Therefore, the binding of tremelimumab to CTLA-4
efﬁciently competes with B7-1/2 binding to CTLA-4, thereby
blocking the function of CTLA-4 in cancer.
Discussion
Checkpoint-blocking antibodies have ensured signiﬁcant advances
in cancer therapy and provided a new weapon against cancer.
The durability of this immunotherapy largely exceeds that
of other forms of anticancer therapy and sometimes enables
long-term remission where patients exhibit no clinical signs
of cancer for many years. However, monotherapies of these
drugs elicit the therapeutic beneﬁt only in a fraction of
patients treated. As a critical next step in the progress toward
improving clinical responses, combination immunotherapies have
been intensively investigated39–41. Combinations of anti-CTLA-4
or anti-PD-1/PD-L1 therapies with other immunotherapies,
chemotherapies, targeted therapies, hormonal therapies and
radiation therapies are being explored. The combination of anti-
CTLA-4 and anti-PD-1 has been the most successful of these
combinations tested so far, probably because CTLA-4 and PD-1
modulate the activity of T-cells at different stages of T-cell
immunity16,26. Thus, dual blockade of CTLA-4 and PD-1 can be a
reasonable and synergistic combination therapy based on their
distinct mechanisms of action. In addition, structural studies of
therapeutic antibodies to reveal their precise epitopes and
therapeutic mechanisms can also facilitate a rational design of
combination immunotherapies, as different epitopes and molecular
mechanisms of therapeutic antibodies can lead to different
therapeutic effects even when therapeutic antibodies target the
same molecule42. Pembrolizumab and nivolumab partially share
epitopes and three-dimensional (3D) space when binding to PD-1,
implying that the mechanisms of antagonism of the two antibodies
are highly similar (Supplementary Fig. 4). These results are
consistent with earlier clinical data showing that the response rate
for both drugs appears similar26; thus, little synergistic therapeutic
effect should be expected from a combination of only these two
drugs.
CTLA-4 exists as a constitutive homodimer generated by an
intermolecular disulphide bond43 (Fig. 8a). Although a single
CTLA-4/tremelimumab Fab complex exists in an asymmetric
unit, a crystallographic two-fold symmetry generates a
homodimeric interface of CTLA-4, which is essentially identical
a b c
Figure 3 | Conformational changes in the loops of PD-1 induced by the
binding of anti-PD-1 antibodies. (a) Superposition of PD-1 molecules
extracted from the complexes of PD-1/PD-L1 (grey, PDB code 4zqk) and PD-
1/pembrolizumab (green), yielding r.m.s. deviation of 1.26Å. (b) Super-
position of PD-1 molecules extracted from the complexes of PD-1/PD-L1
(grey) and PD-1/nivolumab (yellow), yielding r.m.s. deviation of 1.38Å. In a
and b, the BC, C0D, and FG loops of the PD-1 molecule in PD-1/anti-PD-1 are
coloured blue, red and violet, respectively. In b, the N-terminal region (residue
27-33) of the PD-1 molecule in PD-1/nivolumab is coloured orange. This
N-terminal region in PD-1/PD-L1 and PD-1/pembrolizumab and the C0D loop
in PD-1/PD-L1 are not shown in the structures due to the lack of interaction.
(c) Interaction of the C’D loop with pembrolizumab with ribbon repre-
sentation of PD-1 (green) in complex with pembrolizumab Fab (heavy chain:
pale cyan, light chain: pale orange). Surface of the Fv region of pembro-
lizumab is also represented. The C0D loop of PD-1 is coloured red.
a
b
Figure 4 | Crystal structure of PD-L1 in complex with BMS-936559.
(a) Ribbon representation of PD-L1 (yellow) in complex with BMS-936559
Fab fragment (heavy chain: green, light chain: purple). PD-1/PD-L1 complex
(PDB code 4zqk) was superimposed onto the PD-L1 molecule in the
complex of PD-L1/BMS-936559 with mixed ribbon/surface representation.
PD-1 and PD-L1 in PD-1/PD-L1 complex are coloured pale blue and blue,
respectively. The orientation of the PD-1/PD-L1 complex is same as that of
Fig. 1a,c. (b) Stereoview of the 2fo-fc composite omit map (1.2s contour
level) at the interface between PD-L1 (yellow) and BMS-936559 (heavy
chain: green, light chain: purple) calculated at 2.8Å resolution.
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to that observed in the structures of free CTLA-4 or CTLA-4
in complex with B7-1, B7-2, and engineered lipocalin 2
(refs 28,29,38,44), implying that tremelimumab binding does
not affect the homodimerization of CTLA-4 (Fig. 8b). In the
crystal structures of CTLA-4 in complex with B7-1 or B7-2, the
crystal packing generates an alternating periodic arrangement in
which bivalent CTLA-4 homodimers connect bivalent B7-1/2
homodimers, providing a model describing the assembly of
CTLA-4 and B7-1/2 at the interface between a T-cell and cancer
cell28,29 (Fig. 8c). In this model, the CTLA-4/B7 complex is
expected to span a distance of B140Å, which includes the stalk
regions connecting these molecules to the opposing cell
membranes. This distance is compatible with other ligand–
receptor interactions at the central zone of the immunological
synapse, suggesting that this oligomeric arrangement of CTLA-4/
B7 complex can facilitate the efﬁcient use of low-abundance
CTLA-4 at the T-cell surface, thereby promoting the inhibitory
signalling of CTLA-4 and decreasing the local concentration of
CD28 through simple steric crowding28,29,45. As tremelimumab is
an IgG2 antibody, it is capable of binding two CTLA-4 molecules
with high avidity through Y-shaped bivalent presentation; the
dimension of the CTLA-4/tremelimumab complex is estimated
to span 150–190Å. This distance is incompatible with the
oligomeric array of the CTLA-4/B7 complex (Fig. 8d). Therefore,
in addition to simple antagonism of the interaction between
CTLA-4 and B7-1/2, tremelimumab binding could prevent or
disrupt the uniquely organized assembly of the CTLA-4/B7
complex within the immunological synapse.
Despite the clinical success of checkpoint-blocking antibodies,
biologics such as therapeutic antibodies have several short-
comings, including the high cost, limited half-life and immuno-
genicity caused by multiple dosages. As an alternative treatment
strategy to overcome the drawbacks of passive antibody-based
therapy, several small-molecule immunomodulators targeting the
PD-1/PD-L1 axis have been reported46–50. While most of them
are based on peptidomimetics, a recent structural study with the
ﬁrst nonpeptidic chemical inhibitor of the PD-1/PD-L1
interaction revealed that this compound binds to PD-L1 and
induces dimerization of PD-L1, thus occluding the PD-1 binding
site of PD-L1 (ref. 51). Interestingly, the complex structure of
CTLA-4/tremelimumab Fab provided insight for the design of a
small-molecule modulator that interferes with the CTLA-4/B7
signal pathway. Nine of ten residues in the HCDR3 loop (residues
101–110 of the heavy chain) of tremelimumab are involved in the
interaction with CTLA-4 (Fig. 7a). In addition, the binding site of
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Figure 5 | Interaction between PD-L1 and BMS-936559. (a) Stereoview of
the detailed PD-L1/BMS-936559 interface. The carbon atoms of PD-L1 and
heavy and light chain of BMS-936559 are coloured grey, green and purple,
respectively. Hydrogen bonds and a salt bridge are indicated with dashed
lines. (b) Surface representations of the PD-L1 molecules in the complex
structures of PD-1/PD-L1 (left) and PD-1/BMS-936559 (right). The surface
of PD-L1 in PD-1/PD-L1 is coloured blue and the PD-1 binding site on the
surface of PD-L1 is coloured pale blue. The surface of PD-1 in PD-1/BMS-
936559 is colored yellow. The epitope regions for the heavy and light chain
of BMS-936559 are coloured red and purple, respectively.
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c
Figure 6 | Crystal structure of CTLA-4 in complex with tremelimumab.
(a,b) Ribbon representation of CTLA-4 (purple) in complex with
tremelimumab Fab fragment (heavy chain: blue, light chain: cyan). In a, the
CTLA-4(grey)/B7-1(orange) complex (PDB code 1i8l) was superimposed
onto the CTLA-4 molecule in the CTLA-4/tremelimumab complex with a
mixed ribbon/surface representation. In b, the CTLA-4(grey)/B7-2(orange)
complex (PDB code 1i85) was superimposed onto CTLA-4 in the CTLA-4/
tremelimumab complex with a mixed ribbon/surface representation.
(c) Stereoview of the 2fo-fc composite omit map (1.2s contour level) at the
interface between CTLA-4 (purple) and tremelimumab (heavy chain: blue,
light chain: cyan) calculated at 2.0Å resolution.
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the HCDR3 loop overlaps part of the binding site of B7-1/2 on
the surface of CTLA-4 (Fig. 9a). Additionally, heavyR101 and
heavyY110 are located closely enough to be connected directly by a
peptide bond (Fig. 9b). This extensive interaction and the
structural features of the HCDR3 loop in the CTLA-4/
tremelimumab complex suggest that cyclic peptides based on
the HCDR3 sequence may also prevent binding of B7-1/2 to
CTLA-4 (Fig. 9c). As the HCDR3 loop conformation in the
complex is essentially identical to that of tremelimumab Fab
alone, other CDRs and framework regions of tremelimumab
likely contribute to the conformation of HCDR3, implying that
antibody context is important for the proper display of the
tremelimumab HCDR3 (Supplementary Fig. 1c). If this is indeed
the case, a cyclic peptide approach would not be so promising
because of its intrinsic conformational ﬂexibility. Nonetheless, a
cyclic peptide or peptidomimetic approach based on the HCDR3
sequence in combination with the power of phage-display library
technology may facilitate the discovery of small-molecule
modulators of the CTLA-4/B7 interaction, providing an
alternative treatment strategy to overcome the drawbacks of
antibody–based drugs.
In summary, the elucidation of the crystal structures of the
checkpoint molecules PD-1, PD-L1 and CTLA-4 in complex with
the Fab fragments of therapeutic antibodies sheds light on the
molecular mechanisms underlying the therapeutic activity of
these monoclonal antibodies. In addition, the precise epitopes
revealed by the present complex structures should provide useful
information for the improvement of current therapeutic anti-
bodies and development of more effective immunotherapeutic
combination strategies and small-molecule modulators that can
attenuate checkpoint signalling.
Methods
Expression and puriﬁcation of checkpoint proteins. Genes encoding the ecto-
domains of human PD-1 (aa 26–150), human PD-L1 (aa 18–134) and human
CTLA-4 (aa 1–126) were subcloned into pET-21a (Novagen), respectively. A Cys to
Ser mutation was introduced at position 93 of PD-1 to aid expression and folding.
All proteins were expressed in E. coli BL21(DE3) as inclusion bodies. The cells were
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Figure 7 | Interaction between CTLA-4 and tremelimumab. (a) Stereoview of the detailed CTLA-4/tremelimumab interface. The carbon atoms CTLA-4
and heavy and light chain of tremelimumab are coloured grey, green and purple, respectively. Hydrogen bonds and a salt bridge are indicated with dashed
lines. (b) Surface representations of the CTLA-4 molecules in the complex structures of CTLA-4/B7-1 (left), CTLA-4/B7-2 (centre) and CTLA-4/
tremelimumab (right). The surfaces of CTLA-4 in CTLA-4/B7-1 and CTLA-4/B7-2 are coloured grey and the B7-1 or B7-2 binding site on the surface of
CTLA-4 is coloured orange. The surface of CTLA-4 in CTLA-4/tremelimumab is colored purple. The epitope regions for the heavy and light chain of
tremelimumab are coloured blue and cyan, respectively.
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grown at 37 C in LB medium supplemented with 50 mgml 1 ampicillin until
OD600 reached 0.6–1.0, and the protein expression was induced with 1mM IPTG
and incubated for 4 h at 37 C. The cells were harvested by centrifugation,
re-suspended in lysis buffer (20mM Tris, pH 8.0, 200mM NaCl) and lysed by
sonication on ice. Inclusion bodies were recovered by centrifugation (25,000g for
0.5 h at 4 C) and solubilized in 8M urea, 20mM Tris, pH 8.0, 200mM NaCl by
stirring overnight. After removing undissolved residue by centrifugation (25,000g
for 0.5 h at 4 C), solubilized fraction was applied to HisTrap HP column (GE
Healthcare Life Sciences) and washed with ﬁve column volumes of wash buffer
(8M urea, 20mM Tris, pH 8.0, 200mM NaCl, 50mM imidazole). The protein was
then eluted with elution buffer (8M urea, 20mM Tris, pH 8.0, 200mM NaCl,
400mM imidazole). The eluted protein was refolded by dialysis three times
against 20mM Tris, pH 8.0, 200mM NaCl and puriﬁed further by gel ﬁltration
chromatography using a HiLoad 16/60 Superdex 200 pg column (GE Healthcare
Life Sciences). The protein purity was evaluated by reducing and nonreducing
SDS–PAGE.
Expression and puriﬁcation of Fab fragments. The DNA sequences for the Fab
fragments of pembrolizumab, nivolumab, BMS-936559 and tremelimumab were
synthesized after codon-optimization for expression in E. coli (Bioneer, Inc). The
sequences for heavy chain and light chain were cloned into a modiﬁed pBAD
vector, containing the STII signal sequence in each chain for periplasmic secretion
and a C-terminal 6His-tag in heavy chain. The plasmid pBAD-Fab was trans-
formed into E. coli Top10F (Invitrogen). The cells were grown at 37 C in LB
medium supplemented with 50mgml 1 ampicillin. At an OD600 of 1.0, the protein
expression was induced with 0.2% arabinose and cells were grown at 30 C for 15 h.
The cells were harvested by centrifugation, re-suspended in lysis buffer (20mM
Tris, pH 8.0, 200mM NaCl) and lysed by sonication on ice. After removing cell
debris by centrifugation (25,000g for 0.5 h at 4 C), the supernatant containing
soluble protein was applied to HisTrap HP column (GE Healthcare Life Sciences)
and washed with ﬁve column volumes of wash buffer (20mM Tris, pH 8.0,
300mM NaCl, 50mM imidazole). The protein was then eluted with elution buffer
(20mM Tris, pH 8.0, 300mM NaCl, 400mM imidazole). The eluted protein was
concentrated for gel ﬁltration chromatography using a HiLoad 16/60 Superdex
200 pg column (GE Healthcare Life Sciences). The column had previously been
equilibrated with gel ﬁltration buffer (20mM Tris, pH 8.0, 300mM NaCl). The
elution proﬁle of the protein showed a single major peak and the protein quality
was evaluated by reducing and nonreducing SDS–PAGE.
Cancer cell membrane
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T-cell membrane
T-cell membrane
150–190 Å
Cancer cell membrane
Figure 8 | Hypothetical model for prevention of an alternating
arrangement of bivalent dimers of CTLA-4 and B7-1/2 by tremelimumab
binding. (a) Structure of CTLA-4 dimer (purple) binding to two B7-1
molecules (green) (PDB code 1i8l). (b) Structure of CTLA-4 dimer (purple)
binding to two tremelimumab Fab fragments (heavy chain: blue, light chain:
cyan) in the crystal. (c) Suggested model for an alternating periodic
arrangement of bivalent dimers of CTLA-4 and B7-1 at the interface
between a T-cell and cancer cell, imposing an intercellular distance of
B140Å23,24. (d) Suggested model for the bivalent interaction of
tremelimumab with CTLA-4. Tremelimumab binds two CTLA-4 molecules
in the vicinity of the two binding site of IgG, spanning 150–190Å in the
perpendicular direction from the T-cell membrane.
R101
Y110 Y110
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c
Figure 9 | Suggestion of a cyclic peptide as a modulator of the CTLA-4/B7
interaction. (a) Surface representations of the CTLA-4 molecule in the
CTLA-4/B7-1 complex (left, PDB code 1i8l). The B7-1 binding site on the
surface of CTLA-4 is coloured orange. Surface representations of CTLA-4 in
the complex structures of CTLA-4/tremelimumab (right). The HCDR3 loop
binding site on the surface of CTLA-4 is coloured blue. The overlapping
region between the binding sites of B7-1 and HCDR3 is coloured red on the
surface of CTLA-4 (centre). (b) Stereoview of the HCDR3 loop in the
structure of CTLA-4/tremelimumab. The dashed line suggests a peptide
bond between R101 and Y110 for generating a cyclic peptide. (c) Stereoview
of a hypothetical model of the interaction between CTLA-4 (electrostatic
surface representation) and the cyclic peptide based on the HCDR3
sequence of tremelimumab (yellow stick). The cyclic peptide was generated
by connecting R101 and Y110 of the HCDR3 loop in the structure of
CTLA-4/tremelimumab through a peptide bond, and its structure was
polished by regularization and real space reﬁnement in COOT (ref. 52). In
this model, the cyclic peptide retains all of the interactions of HCDR3 in the
structure of CTLA-4/tremelimumab.
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Crystallization and structure determination. Details of the crystallization and
structure determination of the nivolumab Fab, tremelimumab Fab, PD-1/pem-
brolizumab Fab complex, PD-1/nivolumab Fab complex, PD-L1/BMS-936559 Fab
complex, CTLA-4/tremelimumab Fab complex are described in Supplementary
Methods. Data collection and reﬁnement statistics are summarized in Table 1.
Data availability. The atomic coordinates and structure factors have been
deposited in the Protein Data Bank under accession codes 5GGQ, 5GGR, 5GGS,
5GGT, 5GGU and 5GGV. All additional experimental data are available from the
corresponding author on request.
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